Crystal Pharmatech, established in 2010, is a global company with approximately 250 employees and three R&D centers located in Suzhou (China), New Jersey (USA), and Toronto (Canada). Our key differentiator is our integrated and specialized services, including API solid-state research, crystallization, preformulation, formulation development, and manufacturing.
With an average of 15 years of experience, our scientific leadership team has successfully delivered over 100 early phase and 19 commercialized products for global pharmaceutical companies. We have served over 1,000 clients, supporting more than 2,000 new chemical entities.
Leveraging our unique expertise, we collaborate with you to design and develop the most suitable crystal form and formulation for further development. Our guiding principle of "getting the crystal form and formulation right the first time for Phase I" not only expedites the progression of your molecule to IND filing and Phase I clinical trials, but also minimizes the necessity for human PK bridging studies. This approach saves valuable time and reduces costs as your program moves forward to Phase II or subsequent clinical trials.